Find your next paid study

Alliance for Clinical Trials in OncologyNCT07283939

Observational

A Pilot Study of Spatially Fractionated Radiation Therapy in Patients With Extra-Cranial Soft Tissue Metastases

The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereota…

Invasive Ductal Breast CarcinomaInvasive Ductal Breast Carcinoma Stage IVLobular Breast Carcinoma+12 more

Memorial Sloan Kettering Cancer CenterNCT05837767

Solid Tumor, AdultNon-small Cell Lung CancerMelanoma

A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated…

Pierre Fabre MedicamentNCT04913285

~$10 – $7,500

Locally Advanced (Unresectable) or Metastatic Solid Tumors

A Phase 1 Dose Escalation and Expansion Study of NEOK001, a B7-H3 and ROR1 Targeting Bispecific Antibody-Drug Conjugate, in Participants With Select, Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors

This is a first in human (FIH), Phase 1, dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfil…

NEOK Bio, Inc.NCT07612176

~$10 – $8,750

Locally Advanced or Metastatic Malignant Solid Tumors

A Phase 1b/2 Study of ASP2998 as Monotherapy and in Combination With Standard Therapies in Participants With Locally Advanced Unresectable or Metastatic Solid Tumors

Specific proteins found in tumors help the tumors spread and grow. People with solid tumors often have a protein called TROP2 in their tumor. ASP2998 is being …

Astellas Pharma Global Development, Inc.NCT07287995

~$10 – $8,750

Phase 2

Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)

This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or…

Lung Non-Small Cell Carcinoma

Alliance for Clinical Trials in OncologyNCT07293247

Non-Small Cell Lung CancerColorectal CancerBreast Cancer+3 more

A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and to…

Fate TherapeuticsNCT07216105

~$10 – $8,750

Small Cell Lung CancerLarge Cell Neuroendocrine Lung CarcinomaExtrapulmonary Neuroendocrine Carcinoma of Small Cell Histology+1 more

A Phase Ib/II, Open-label, Safety and Tolerability Trial of Obrixtamig in Combination With ZL-1310 in Patients With Poorly Differentiated NEC

This study is open to adults with advanced small cell lung cancer and other neuroendocrine cancers. The study has 2 parts. The purpose of Part 1 is to find a s…

Boehringer IngelheimNCT07707895

~$10 – $7,500

Phase 3

Phase III Evaluation of Fixed Duration Zanubrutinib Plus Sonrotoclax-Based Therapy Compared to Continuous Zanubrutinib in Previously Untreated Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic l…

Chronic Lymphocytic LeukemiaSmall Lymphocytic Leukemia

Alliance for Clinical Trials in OncologyNCT07321652

MesotheliomaNon Small Cell Lung CancerMalignant Peripheral Nerve Sheath Tumors+3 more

A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable…

Bristol-Myers SquibbNCT05245500

~$10 – $7,500

Intractable PainPalliative Care

An Open-Label, Phase 1b Safety and Efficacy Trial of Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain

Background: Cancer-induced bone pain (CIBP) is common in people with cancer. Bone cancer can also lead to anxiety, depression, and reduced mobility and qualit…

National Institute of Neurological Disorders and Stroke (NINDS)NCT02522611

~$10 – $5,625

Ewing SarcomaDesmoplastic Small Round Cell TumorPediatric Cancer+1 more

Lurbinectedin in FET-Fusion Tumors (LIFFT)

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed …